OLIMEL N7E EMULSION FOR INFUSION

Introduction

Leaflet: information for the user

Olimel N7E emulsion for infusion

Read the entire leaflet carefully before this medicine is administered to you, as it contains important information for you.

• Keep this leaflet, as you may need to read it again.
• If you have any questions, ask your doctor or nurse.
• If you experience side effects, ask your doctor or nurse, even if they are side effects not listed in this leaflet. See section 4.

Contents of the leaflet

1. What Olimel N7E is and what it is used for
2. What you need to know before Olimel N7E is administered to you
3. How Olimel N7E will be administered to you
4. Possible side effects
5. Storage of Olimel N7E
6. Contents of the pack and further information

1. What OLIMEL N7E is and what it is used for

Olimel is an emulsion for infusion. It comes in a bag with 3 chambers

One chamber contains a glucose solution with calcium, the second contains a lipid emulsion, and the third contains an amino acid solution with other electrolytes.

Olimel is used to feed adults and children over 2 years of age through a tube in a vein when normal feeding by mouth is not possible

Olimel should only be used under medical supervision.

2. What you need to know before Olimel N7E is administered to you

OlimelN7Emust not be administered:

• To premature neonates, babies, and children under 2 years of age
• If you are hypersensitive (allergic) to egg proteins, soybean proteins, peanut proteins, corn/maize products (see also the section "Warnings and precautions" below) or any of the other components of this medicine (listed in section 6).
• If your body has problems using certain amino acids.
• If you have a particularly high level of fats in the blood
• If you have hyperglycemia (too much sugar in the blood)
• If you have an abnormally high level of some electrolyte (sodium, potassium, magnesium, calcium, and/or phosphorus) in the blood.

In all cases, your doctor will decide whether you should be given this medicine based on factors such as your age, weight, and clinical condition, along with the results of all tests performed.

Warnings and precautions

Consult your doctor or nurse before Olimel is administered to you.

Too rapid administration of total parenteral nutrition (TPN) solutions may cause injury or death.

The infusion must be stopped immediately if any abnormal signs or symptoms of an allergic reaction (such as sweating, fever, chills, headache, skin rash, or difficulty breathing) develop. This medicine contains soybean oil and egg phospholipids. Soybean and egg proteins may cause hypersensitivity reactions. Cross-allergic reactions have been observed between soybean and peanut proteins.

Olimel contains glucose derived from corn, which may cause hypersensitivity reactions if you are allergic to corn or corn products (see section "Olimel N7E must not be administered" above).

Difficulty breathing could also be a sign that small particles have formed in the lungs, blocking blood vessels (pulmonary vascular precipitates). If you experience any difficulty breathing, inform your doctor or nurse. They will decide on the course of action to take.

The antibiotic called ceftriaxone must not be mixed or administered simultaneously with solutions containing calcium (including Olimel) given by drip into a vein.

These medicines must not be administered together, even through different lines or infusion sites.

However, Olimel and ceftriaxone may be administered sequentially, one after the other, if infusion lines are used at different points, or if the infusion lines are replaced or thoroughly flushed with physiological saline solution between infusions to avoid the formation of precipitates (formation of ceftriaxone and calcium salt particles).

Certain medicines and diseases may increase the risk of developing infections or sepsis (bacteria in the blood). There is a risk of infection or sepsis, especially when a tube (intravenous catheter) is inserted into a vein. Your doctor will closely monitor you for signs of infection.

Patients who require parenteral nutrition (administration of nutrients through a tube inserted into a vein) may be more prone to infections due to their medical condition. The use of "aseptic techniques" (germ-free) when inserting and maintaining the catheter and preparing the nutritional formula (TPN) can reduce the risk of infection.

If you are severely malnourished to the point of needing intravenous feeding, your doctor will start treatment slowly. Additionally, you will be monitored to avoid sudden changes in your fluid, vitamin, electrolyte, and mineral levels.

Before starting the infusion, any metabolic disorders and water and salt balance in your body must be corrected. Your doctor will monitor your condition while you are being administered this medicine and may change the dose or add other nutrients, such as vitamins, electrolytes, and trace elements, if deemed necessary.

Cases of liver disorders, including problems with bile elimination (cholestasis), fat storage (hepatic steatosis), fibrosis, which may lead to liver failure, as well as cholecystitis and cholelithiasis, have been reported in patients receiving intravenous nutritional treatment. It is believed that the cause of these disorders is due to multiple factors and may differ between patients. If you experience symptoms such as nausea, vomiting, abdominal pain, yellowing of the skin or eyes, consult your doctor to identify possible causative and contributing factors and potential therapeutic and preventive measures.

Your doctor should be aware if you have:

• any severe kidney problem. You should also inform your doctor if you are receiving dialysis treatment (artificial kidney) or if you have any other type of treatment to clean the blood
• any severe liver problem
• any blood coagulation problem
• abnormal functioning of the adrenal glands (adrenal insufficiency). The adrenal glands are triangular in shape and are located above the kidneys
• heart failure
• lung disease
• fluid accumulation in the body (hyperhydration)
• insufficient water in the body (dehydration)
• excess sugar in the blood (diabetes mellitus) without treatment for it
• heart attack or shock due to sudden heart failure
• severe metabolic acidosis (blood too acidic)
• generalized infection (septicemia)
• coma

To check the effectiveness and safety of administration, your doctor will perform laboratory and clinical tests while you are being administered this medicine. If you are administered this medicine for several weeks, your blood will be regularly analyzed.

The decrease in the body's ability to eliminate the fats contained in this medicine may lead to a "fat overload syndrome" (see section 4 "Possible side effects").

If during the infusion you notice pain, burning, or swelling at the infusion site or leakage of the infusion, inform your doctor or nurse. The administration will be stopped immediately and resumed in another vein.

If your blood sugar levels rise too high, your doctor will adjust the rate of Olimel administration or provide you with medication to control blood sugar levels (insulin).

Olimel can only be administered through a tube (catheter) connected to a large vein in your chest (central vein).

Children and adolescents

If your child is under 18 years of age, special attention will be paid to the administration of the correct dose. Additional precautions will also be taken due to the increased sensitivity of children to the risk of infection. Supplementation with vitamins and trace elements is always necessary. Pediatric formulations should be used.

Use ofOlimelwith other medicines

Tell your doctor if you are taking or using, have recently taken or used, or might take or use any other medicine.

Concomitant absorption of other medicines is generally not a contraindication. If you are taking other medicines, prescribed or not, you should consult your doctor in advance so that they can check for compatibility.

Inform your doctor if you are taking or receiving any of the following medicines:

• insulin
• heparin

Olimel must not be administered simultaneously with blood through the same infusion line.

Olimel contains calcium. It must not be administered together or through the same line with the antibiotic ceftriaxone, as particles may form. If the same device is used to administer these medicines sequentially, it must be thoroughly flushed

Due to the risk of precipitation, Olimel must not be administered through the same infusion line or mixed with the antibiotic ampicillin or the antiepileptic fosphenytoin.

The olive and soybean oils present in Olimel contain vitamin K. This usually does not affect blood-thinning medicines (anticoagulants) such as coumarin. However, if you take anticoagulants, you should inform your doctor.

The lipids in this emulsion may interfere with the results of certain laboratory tests if the blood sample is taken before they have been eliminated from your bloodstream (usually after a period of 5 to 6 hours without receiving lipids).

Olimel contains potassium. Special care should be taken in patients who take diuretics, ACE inhibitors, angiotensin II receptor antagonists (medicines for high blood pressure), or immunosuppressants. These classes of medicines may increase potassium levels in the blood.

Pregnancy and breastfeeding

If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor before this medicine is administered to you.

There is no sufficient experience with the use of Olimel in pregnant or breastfeeding women. Olimel may be used during pregnancy and breastfeeding if necessary. Olimel should only be administered to pregnant or breastfeeding women after careful consideration.

Driving and using machines

Not applicable.

3. How Olimel N7E will be administered to you

Dose

Olimel should only be administered to adults and children over 2 years of age.

This is an emulsion for infusion, i.e., for administration through a tube (catheter) into a large vein in your chest.

Olimel should be at room temperature before use.

Olimel is for single use only.

Dose – Adults

Your doctor will determine an infusion rate based on your needs and clinical condition.

Administration can continue for as long as necessary, depending on your clinical condition.

Dose – Children over 2 years and adolescents

The doctor will decide on the dose and the duration of administration, based on age, weight, height, clinical condition, and the body's ability to break down and use the ingredients of OLIMEL.

If you have been administered too muchOlimelN7E

If the dose administered is too high or the infusion is too rapid, the amino acid content may make your blood too acidic, and signs of hypervolemia (increased circulating blood volume) may occur. Your blood and urine glucose levels may increase, a hyperosmolar syndrome may develop, and the lipid content may increase triglycerides in your blood. Administration of an excessively rapid or excessive volume of Olimel may cause nausea, vomiting, chills, headache, fever, sweating (hyperhidrosis), and electrolyte disturbances. In this case, the infusion should be stopped immediately.

In some severe cases, your doctor may need to perform temporary renal dialysis to help your kidneys eliminate excess product.

To avoid these cases, your doctor will regularly monitor your condition and analyze your blood parameters.

If you have any further questions on the use of this product, ask your doctor.

In case of overdose or accidental ingestion, consult the Toxicology Information Service. Phone 915.620.420

4. Possible side effects

Like all medicines, this medicine may cause side effects, although not everybody gets them. If you notice that you do not feel as you did before, inform your doctor or nurse immediately.

The tests that your doctor will perform while you are taking this medicine should minimize the risk of side effects.

If any abnormal signs or symptoms of an allergic reaction, such as sweating, fever, chills, headache, skin rash, or difficulty breathing, develop, the infusion should be stopped immediately.

The following side effects have been reported with Olimel:

Frequency – common: may affect up to 1 in 10 people

• Fast heart rate (tachycardia).
• Decreased appetite.
• Increased level of fats in the blood (hypertriglyceridemia).
• Abdominal pain.
• Diarrhea.
• Nausea.
• High blood pressure (hypertension).

Frequency - Unknown: cannot be estimated from the available data

• Hypersensitivity reactions, including sweating, fever, chills, headache, skin rash (erythematous, papular, pustular, macular, generalized rash), itching, flushing, difficulty breathing
• Infusion site reactions, including pain, irritation, swelling/edema, redness (erythema)/heat, cell death (necrosis) or blisters/vesicles, inflammation, thickening, or constriction of the skin
• Vomiting.

The following side effects have been reported with other similar products for parenteral nutrition:

Frequency - Very rare: may affect up to 1 in 10,000 people

• Reduced ability to eliminate lipids (fat overload syndrome) associated with a sudden and severe worsening of the patient's medical condition. The following symptoms of fat overload syndrome are usually reversible when the lipid emulsion infusion is stopped:
• • Fever.
  • Decreased red blood cells, which can cause paleness, weakness, or difficulty breathing (anemia).
  • Low white blood cell count, which can increase the risk of infection (leukopenia).
  • Low platelet count, which can increase the risk of bruising and/or bleeding (thrombocytopenia).
  • Coagulation disorders that affect the blood's ability to clot
  • High levels of fats in the blood (hyperlipidemia).
  • Fatty infiltration of the liver (hepatomegaly).
  • Worsening of liver function.
  • Central nervous system symptoms (e.g., coma).

Frequency - Unknown: cannot be estimated from the available data

• Allergic reactions.
• Problems with bile elimination (cholestasis).
• Abnormal liver function tests.
• Enlargement of the liver (hepatomegaly).
• Diseases associated with parenteral nutrition (see "Warnings and precautions" in section 2).
• Jaundice.
• Decreased platelet count (thrombocytopenia).
• Increased levels of nitrogen in the blood (azotemia).
• Increased liver enzymes.
• Formation of small particles that can lead to blockage of blood vessels in the lungs (pulmonary vascular precipitates), resulting in pulmonary vascular embolism and difficulty breathing (respiratory distress).

Reporting of side effects:

If you experience any side effects, consult your doctor or nurse, even if they are side effects not listed in this leaflet. You can also report them directly through the Spanish Pharmacovigilance System for Human Use Medicines: https://www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medicine.

5. Storage of Olimel N7E

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date stated on the packaging and outer packaging (MM/YYYY). The expiry date is the last day of the month indicated.

Do not freeze.

Store in the overbag.

Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.

6. Container Content and Additional Information

Composition ofOlimelN7E

The active principles of each bag of the reconstituted emulsion are a solution of L-amino acids at 11.1% (corresponding to 11.1g/100 ml of alanine, arginine, glycine, histidine, isoleucine, leucine, lysine (as lysine acetate), methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine, aspartic acid, glutamic acid) with electrolytes (sodium, potassium, magnesium, phosphate, acetate, chloride), a lipid emulsion at 20% (corresponding to 20 g/100 ml of refined olive oil and refined soybean oil) and a glucose solution at 35% (corresponding to 35 g/100 ml as glucose monohydrate) with calcium.

The other components are:

Appearance ofOlimel N7Eand Container Content

Olimel is an emulsion for perfusion conditioned in a 3-compartment bag. One compartment contains a lipid emulsion, another an amino acid solution with electrolytes, and the third a glucose solution with calcium. These compartments are separated by non-permanent seals. Before administration, the content of the compartments must be mixed by rotating the bag from top to bottom until the seals are open.

Appearance before reconstitution:

• The amino acid and glucose solutions are transparent, colorless, or slightly yellowish.
• The lipid emulsion is homogeneous and milky white.

Appearance after reconstitution: Homogeneous milky emulsion.

The tricompartmental bag is a plastic bag with several layers. The material of the inner layer (contact) of the bag is designed to be compatible with the authorized components and additives

To avoid contact with air oxygen, the bag is packaged in an outer bag that acts as an oxygen barrier, which contains a sachet with an oxygen absorber.

Container Sizes

1000 ml bag: 1 cardboard box with 6 bags

1500 ml bag: 1 cardboard box with 4 bags

2000 ml bag: 1 cardboard box with 4 bags

1 bag of 1000 ml, 1500 ml, and 2000 ml

Only some container sizes may be marketed.

Marketing Authorization Holder

Baxter S.L.

Pouet de Camilo 2, 46394 Ribarroja del Turia (Valencia)

Manufacturer

Baxter S.A., Boulevard René Branquart, 80, 7860 Lessines, Belgium

This medicinal product is authorized in the Member States of the European Economic Area under the following names:

France, Portugal, Estonia, Poland, Lithuania, Bulgaria, Romania, Latvia, Czech Republic, Belgium, Spain, Slovakia, Netherlands, Luxembourg, Slovenia, Italy, Greece, Cyprus: OLIMEL N7E

In some countries, it is registered under different names as described below:

Austria: ZentroOLIMEL 4.4% mit Elektrolyten

Germany: Olimel 4.4% E

Denmark, Iceland, Sweden, Norway, Finland: Olimel N7E

United Kingdom, Ireland, and Malta: Triomel 7g/l nitrogen 1140 kcal/l with electrolytes

Date of the last revision of this leafletApril 2020

Detailed and updated information on this medicinal product is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/

This information is intended only for healthcare professionals

Pharmacotherapeutic group: solutions for parenteral nutrition / combinations

ATC code: B05 BA10.

• Qualitative and quantitative composition

Olimel is presented in the form of a 3-compartment bag. Each bag contains a glucose solution with calcium, a lipid emulsion, and an amino acid solution with other electrolytes

After mixing the content of the 3 compartments, the composition of the reconstituted emulsion is indicated in the following table for each bag size.

(a) Mixture of refined olive oil (approximately 80%) and refined soybean oil (approximately 20%) corresponding to a ratio of essential fatty acids / total fatty acids of 20%

The excipients are:

The reconstituted emulsion provides the following for each bag size:

a Includes calories from purified egg phospholipids

b Includes phosphate provided by the lipid emulsion

• Dosage and administration

Dosage

Olimel is not recommended for use in children under 2 years of age, as neither the composition nor the volume is suitable (see sections 4.4, 5.1, and 5.2 of the Technical Sheet).

The maximum daily dose mentioned below should not be exceeded. Due to the invariant composition of the multicompartimental bag, the ability to simultaneously satisfy all the patient's nutritional needs may not be possible. There may be clinical situations in which the patient requires amounts of nutrients that vary from the composition of the bag. In this situation, the impact of any volume adjustment (dose) and the resulting effect on the dosing of the rest of Olimel's nutrients should be considered.

In adults

The dose depends on the patient's energy expenditure, clinical status, body weight, and ability to metabolize Olimel's components, as well as any additional energy or proteins administered orally or enterally. Therefore, the appropriate bag size should be chosen.

The average daily needs are:

• From 0.16 to 0.35 g of nitrogen/kg of body weight (from 1 to 2 g of amino acids/kg), depending on the patient's nutritional status and level of catabolic stress.
• From 20 to 40 kcal/kg.
• From 20 to 40 ml of liquid/kg, or from 1 to 1.5 ml per kcal spent.

For Olimel, the maximum daily dose is defined by the total caloric intake, 40 kcal/kg provided in a volume of 35 ml/kg, corresponding to 1.5 g/kg of amino acids, 4.9 g/kg of glucose, and 1.4 g/kg of lipids, 1.2 mmol/kg of sodium, and 1.1 mmol/kg of potassium. For a 70 kg patient, this would be equivalent to 2450 ml of Olimel per day, which would provide 108 g of amino acids, 343 g of glucose, and 98 g of lipids, i.e., 2352 non-protein kcal and 2793 total kcal.

Normally, the administration rate should be gradually increased during the first hour and then adjusted according to the dose being administered, daily volume intake, and duration of perfusion.

For Olimel, the maximum perfusion rate is 1.7 ml/kg/hour, corresponding to 0.08 g/kg/hour of amino acids, 0.24 g/kg/hour of glucose, and 0.07 g/kg/hour of lipids.

In children over 2 years and adolescents

No studies have been conducted in the pediatric population.

The dose depends on the patient's energy expenditure, clinical status, weight, and ability to metabolize Olimel's components, as well as any additional energy or proteins administered orally or enterally. Therefore, the appropriate bag size should be chosen.

Additionally, the daily needs for fluid, nitrogen, and energy decrease continuously with age: Two age groups are considered, one between 2 and 11 years, and another between 12 and 18 years.

For OLIMEL N7E, for both age groups, the limiting factor for the daily dose is the magnesium concentration, while the glucose concentration is the limiting factor for the hourly rate. The resulting intakes are as follows:

a: Recommended values in the 2018 ESPGHAN/ESPEN/ESPR Guidelines

Normally, the administration rate should be gradually increased during the first hour and then adjusted according to the dose being administered, daily volume intake, and duration of perfusion.

In general, in the case of small children, it is recommended to start perfusion with a reduced daily dose and gradually increase it to the maximum dose (see previous point).

Form and duration of administration

For single use.

Once the bag is opened, it is recommended to use its contents immediately and not store it for subsequent infusions.

The appearance of the mixture after reconstitution is a homogeneous emulsion similar to milk.

For instructions on the preparation and handling of the emulsion for infusion, see section 6.6 of the Technical Sheet.

Due to its high osmolarity, Olimel can only be administered through a central vein.

The recommended duration of infusion of a parenteral nutrition bag is between 12 and 24 hours.

Treatment with parenteral nutrition can continue for as long as the patient's clinical condition requires.

• Incompatibilities

No other medication or drug should be added to any of the components of the bag or to the reconstituted emulsion without first confirming the compatibility and stability of the resulting preparation (in particular the stability of the lipid emulsion).

Incompatibilities may occur due to, for example, excess acidity (low pH) or inadequate content of divalent cations (Ca2+ and Mg2+), which can destabilize the lipid emulsion.

As with any parenteral nutrition mixture, the proportions of calcium and phosphate should be taken into account. Excessive addition of calcium and phosphate, especially in the form of mineral salts, can cause the formation of calcium phosphate precipitates.

Olimel contains calcium ions, which poses an additional risk of coagulation in anticoagulated/preserved blood with citrate, or its components.

Ceftriaxone should not be mixed or administered with intravenous solutions containing calcium, including Olimel, through the same infusion line (e.g. Y connector) due to the risk of ceftriaxone precipitation with calcium salt (see sections 4.4 and 4.5 of the Technical Sheet). Ceftriaxone and calcium-containing solutions can be administered sequentially one after the other if infusion lines are used at different points, or if infusion lines are replaced or flushed.

Due to the risk of precipitation, Olimel should not be administered through the same infusion line or mixed with ampicillin or fosphenytoin.

Check the compatibility with solutions administered simultaneously through the same administration equipment, catheter, or cannula.

It should not be administered before, simultaneously, or after blood through the same equipment due to the risk of pseudoagglutination.

• Special precautions for elimination and other manipulations

In Table 1, an overview of the preparation steps for the administration of Olimel is provided.

To open

Remove the protective overbag.

Discard the packet with the oxygen absorber.

Confirm the integrity of the bag and the non-permanent seals. Use it only if the bag is not damaged, the non-permanent seals are intact (i.e., the contents of the three compartments have not been mixed), if the amino acid solution and the glucose solution are transparent, colorless, or slightly yellowish, practically free of visible particles, and if the lipid emulsion is a homogeneous liquid with a milky appearance.

Mixing of solutions and emulsion

Ensure that the product is at room temperature when the non-permanent seals are broken.

Manually roll the bag over itself, starting from the top of the bag (hanger end). The non-permanent seals will disappear from the side close to the entrances. Continue rolling until the seals are open approximately halfway through their length.

Mix the bag by inverting it at least 3 times.

The appearance after reconstitution is a homogeneous emulsion similar to milk.

Additions

The bag has sufficient capacity for vitamins, electrolytes, and trace elements to be added.

Any addition (including vitamins) must be made to the reconstituted mixture (after breaking the non-permanent seals and mixing the contents of the three compartments).

Vitamins can also be added to the glucose compartment before reconstituting the mixture (before breaking the non-permanent seals and mixing the contents of the three compartments).

When making additions to formulations containing electrolytes, the amount of electrolytes already present in the bag must be taken into account.

Additions must be carried out by qualified personnel in aseptic conditions.

Olimel can be supplemented with electrolytes according to the following table:

a Value corresponding to the addition of inorganic phosphate

b Including phosphate provided by the lipid emulsion

Trace elements and vitamins:

Stability has been demonstrated with commercially available preparations of vitamins and trace elements (containing up to 1 mg of iron).

Compatibility with other additives can be consulted upon request.

When making additions, the final osmolarity of the mixture should be measured before administering it through a peripheral vein.

To make an addition:

• It must be carried out in aseptic conditions.
• Prepare the injection point of the bag.
• Puncture the injection point and inject the additives using a syringe or a reconstitution device.
• Mix the contents of the bag and the additives.

Preparation of infusion

It must be carried out in aseptic conditions.

Hang the bag.

Remove the plastic protector from the administration outlet.

Firmly insert the tip of the infusion equipment into the administration outlet.

Table 1: Preparation steps for the administration of Olimel

Administration

For single use only.

Administer the product only after the non-permanent seals between the three compartments have been broken and the contents of the three compartments have been mixed.

Ensure that the final emulsion for infusion shows no phase separation.

After opening the bag, the contents must be used immediately. The opened bag should never be stored for subsequent infusion. Do not reconnect a partially used bag.

Do not connect bags in series to avoid the risk of gas embolism due to the gas present in the first bag.

All unused medication, materials that have come into contact with it, and all necessary devices must be discarded.

Extravasation

The catheter area should be regularly inspected to identify signs of extravasation.

If extravasation occurs, administration should be stopped immediately, keeping the cannula or catheter in place for immediate patient treatment. If possible, aspiration should be performed through the inserted cannula/catheter to reduce the amount of fluid present in the tissues before removing the cannula/catheter.

Specific measures should be taken depending on the stage or extent of any injury caused by the extravasated product (including any products mixed with Olimel).

Treatment options may include pharmacological, non-pharmacological, and/or surgical intervention. In the case of significant extravasation, a plastic surgeon should be consulted within the first 72 hours.

The extravasation area should be inspected at least every 4 hours during the first 24 hours and then once a day.

Infusion should not be resumed in the same central vein.